Vaccines for Mump Virus
Mumps is a serious public health problem that can be prevented and controlled by vaccination. The incidence of mumps has decreased significantly after extensive vaccination, but recurrence has occurred in some countries with mumps. Therefore, it is very necessary to develop a vaccine that produces complete protection and prevents the recurrence of mumps. Creative Biolabs has advanced vaccine technology platform and provides a rapid means to afford protection from Mump Virus in an outbreak situation.
Mump Virus
Mump virus (MuV) is a single-stranded minus-strand RNA virus belonging to the genus Rubulavirus within the family Paramyxoviridae, causing an acute respiratory infection which is prevalent in the pre-vaccine era. Mumps is usually spread by droplets with an incubation period of 16-18 days. The infection period begins 5 days before the onset of symptoms and up to 9 days. Mumps patients usually present with parotitis, but at least one-third of the infections are asymptomatic or have non-specific symptoms such as fever and myalgia without mumps. Most of these diseases are self-limiting. Complications such as meningitis, pancreatitis, deafness, and encephalitis may occur, with the most common being orchitis.
Vaccines for Mump Virus
So far, 12 MuV genotypes have been discovered worldwide, of which only 6 have been circulating, including genotypes G, H, C, F, K, and D detected in 25 countries. Live attenuated mumps vaccine, including Jeryl Lynn strain (genotype A), Leningrad-3 strain (genotype N), L-Zagreb strain (genotype N), Rubini strain (genotype A), and Urabe strain (genotype) B), developed from a few MuV genotypes have been available since the 1960s. Because MuV is a single serotype, these mumps vaccines theoretically can protect against viral infections of all MuV genotypes. Mumps vaccine strains are primarily serial passaged through chicken embryo cells or other cells to reduce the virulence of the virus.
As the main immunogenic protein of MuV, hemagglutinin-neuraminidase (HN) plays an important role in humoral immunity against MuV, which can induce the production of neutralizing antibodies. Neutralizing antibodies are critical for vaccine protection, and their levels may be affected by a variety of factors, including antigenic differences between MuV vaccine strain and wild-type strains, vaccination doses, and inherent limitations of mumps protective immunity.
Our Services for Mump Virus Vaccine
- Isolation of virus strains
- MuV vaccine strain development
- Detection of neutralizing antibodies
Mumps is a vaccine-preventable disease, and immunization with the mumps vaccine is the main measure to prevent and control the epidemic of mumps. Creative Biolabs has an advanced vaccine platform that provides global customers with a vaccine that produces high titers of neutralizing antibodies with high protection against mump virus.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
